title: Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.
abstract: We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected withRhizopus delemar.In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.
authors.affiliation: Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA.
authors.forename: Teclegiorgis
authors.initials: T
authors.lastname: Gebremariam
authors.affiliation: Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA.
authors.forename: Sondus
authors.initials: S
authors.lastname: Alkhazraji
authors.affiliation: Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA.
authors.forename: Clara
authors.initials: C
authors.lastname: Baldin
authors.affiliation: Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
authors.forename: Laura
authors.identifier: 0000-0002-4493-4652
authors.initials: L
authors.lastname: Kovanda
authors.affiliation: University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
authors.forename: Nathan P
authors.initials: NP
authors.lastname: Wiederhold
authors.affiliation: Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA ibrahim@labiomed.org.|David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Ashraf S
authors.initials: AS
authors.lastname: Ibrahim
mesh_terms: D000818:Animals; D019072:Antibiotic Prophylaxis / Q000379:methods; D000935:Antifungal Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D007165:Immunosuppression Therapy; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000517:prevention & control*; D051379:Mice; D009091:Mucormycosis / Q000188:drug therapy* / Q000517:prevention & control*; D009570:Nitriles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D012233:Rhizopus / Q000187:drug effects; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole; C101425:posaconazole; D065819:Voriconazole
keywords: Rhizopus delemar; isavuconazole; mucormycosis; murine; posaconazole; prophylaxis; voriconazole